NEI Research News

More than 20 years after the launch of a landmark clinical trial, follow-up examinations and analyses found that not all patients with elevated eye pressure need pressure-lowering treatment to prevent vision loss from glaucoma.

A new study showed that ingesting the compound citicoline restored optic nerve (neural) signals between the brain and eye to near-normal levels in the study rats.

A gene therapy protects eye cells in mice with a rare disorder that causes vision loss, especially when used in combination with other gene therapies, shows a study published in eLife.

LambdaVision, the Farmington, Connecticut-based biotech firm that developed the artificial retina, is exploring optimizing production of an artificial retina in space, in a series of missions to the International Space Station.

Using laboratory-grown roundworms as well as human and mouse eye tissue, researchers have identified a new potential mechanism for age-related macular degeneration—the leading cause of blindness among older adults.

Researchers at Keck School of Medicine of USC develop signals that could bring color vision and improved clarity to prosthesis for the blind.

Not all health care providers speak the same language, but the software in their clinical imaging devices can and should.

Scientists at the University of Pennsylvania School of Veterinary Medicine report findings of a gene therapy to treat a severe form of Leber congenital amaurosis, caused by mutations in the NPHP5 gene.

Early treatment with anti-VEGF injections slowed diabetic retinopathy in a clinical study from the DRCR Retina Network (DRCR.net). However, two years into the four-year study its effect on vision was similar to standard treatment.

NEI-funded research at the University of Rochester has led to the development of a 3D lab model that mimics the part of the human retina affected in age-related macular degeneration.